Stake logo

CDXS

Codexis, Inc.

About CDXS

Codexis, Inc. is an enzyme engineering company. The Company is engaged in discovering, developing and sells enzymes and other proteins. It operates through two segments: Performance Enzymes and Novel Biotherapeutics. The Company’s CodeEvolver technology platform accelerates biologic discovery through the transformation of a starting enzyme into a biocatalyst or therapeutic candidate. The Company has commercialized its CodeEvolver protein engineering technology platform and products in the pharmaceutical’s markets. Its products include biocatalysts, chemical intermediates and Codex biocatalyst panels and kits. It also commercialized three additional enzymes, such as Codex HiFi DNA Polymerase for use in next generation sequencing, Codex HiTemp Reverse Transcriptase for use in molecular diagnostic applications, and Codex HiCap RNA Polymerase for use in RNA synthesis applications. The Company is developing its lead program, CDX-6114 for the treatment of hyperphenylalaninemia (HPA).

Buy US stocks in Australia starting with CDXS. Open an account and start investing today!

Market Capitalisation

$431.56M

Price-earnings ratio

-

Dividend yield

0.00%

Volume

430.17K

High today

$6.72

Low today

$6.34

Open price

$6.41

52-week high

$22.22

52-week low

$4.21


CDXS FAQs

One share of Codexis, Inc. is valued at $6.59.

The ticker symbol for Codexis, Inc. is CDXS.

To buy CDXS stocks in Australia you'll need to open an account with a broker like Stake.
To do so follow these steps:
  1. Sign up in minutes, all you need is some I.D.
  2. Choose Stake Wall St
  3. Deposit directly into your Stake wallet and you're ready to invest in CDXS

As of 29/01/2023 Codexis, Inc. has a market cap of $432M.

The Codexis, Inc. 52-week high stock price is $22.22.

The Codexis, Inc. 52-week low stock price is $4.21.


Related Stocks

This does not constitute financial advice. You should do your own research before making an investment decision. Past performance is not a reliable indication of future performance. No representation is made as to the timeliness, reliability, accuracy or completeness of the market data provided.